Rossari Biotech Ltd reported its unaudited standalone and consolidated financial results for the quarter and half year ended September 30, 2025, during the Board meeting on October 15, 2025. The report includes the approval of stock options under ESOP 2019 and an additional investment of up to USD 8 million in its subsidiary, Rossari International Limited.